In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
Is camrelizumab effective for recurring or resistant classical Hodgkin’s lymphoma?
In a nutshell This study evaluated camrelizumab (SHR 1210) for patients with classical Hodgkin's Lymphoma (cHL) that has come back or is resisting treatment. The authors concluded that this drug is a safe and effective treatment for these patients. Some background After initial treatment, 5-10% of patients with cHL do not...
Read MoreSearching for patients with relapsed/unresponsive non-Hodgkin lymphoma to test an experimental antibody drug
In a nutshell This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States. The details Non-Hodgkin lymphoma (NHL) is a...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreEvaluating GVDex chemotherapy for patients with recurrent or persistent Hodgkin’s lymphoma
In a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....
Read MoreEvaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma
In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....
Read MoreEvaluating BCD chemotherapy for patients with peripheral T-cell lymphoma
In a nutshell This study evaluated the safety and effectiveness of BCD chemotherapy (bendamustine, carboplatin, and dexamethasone) for patients with peripheral T-cell lymphoma that has come back or stopped responding to treatment. This study concluded that this treatment was promising, with minimal side effects. Some background Peripheral T-cell...
Read MoreSearching patients with relapsed or unresponsive cancer to test a new medication
In a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors. The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states. The details Relapsed/refractory...
Read MoreSearching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.
In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...
Read MoreUsing alpha-interferon to treat residual chronic myeloid leukemia after transplantation
In a nutshell This study looked at the effectiveness of interferon-alpha (IntronA) treatment in patients with chronic myeloid leukemia (CML) with residual disease after transplantation. Researchers found that this treatment may be useful in patients with signs of disease after transplant. Some background Chronic myeloid leukemia is a cancer...
Read MoreTreatment options for patients with recurrent or non-responsive Hodgkin lymphoma
In a nutshell This article reviewed current treatment options for patients with Hodgkin lymphoma (HL) that has come back (relapsed) or stopped responding to treatment (refractory). Some background Chemotherapy remains the standard first-line treatment for HL. One of the most commonly used regimens is ABVD (doxorubicin, bleomycin, vinblastine,...
Read More
